Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 6/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2869627 | 0.86 | ALDH1A1 (0.52) | ALDH1A1MAPK1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2863647 | 0.85 | ALDH1A1 (0.47) | ALDH1A1MAPK1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2868509 | 0.85 | S1PR4 (0.44) | ALDH1A1MAPK1SMN1; SMN2LMNAMAPT | |
| SCHEMBL14096252 | 0.85 | HTT (0.61) | ALDH1A1MAPK1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2858952 | 0.85 | ALDH1A1 (0.52) | ALDH1A1MAPK1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2869907 | 0.83 | ALDH1A1 (0.44) | ALDH1A1MAPK1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2863378 | 0.83 | PTGES (0.53) | ALDH1A1MAPK1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2860251 | 0.83 | S1PR1 (0.49) | ALDH1A1MAPK1SMN1; SMN2RAB9ALMNA | |
| SCHEMBL14096002 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MAPK1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2856705 | 0.82 | ALDH1A1 (0.50) | ALDH1A1MAPK1SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365068-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | claimed |
| EP-1747196-A2 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | Achillion Pharmaceuticals, Inc. (US) | 2007-01-31 | — | — | EP | claimed |
| WO-2006083271-A2 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| US-20060025416-A1 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-02-02 | — | — | US | claimed |
| US-7767706-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100029652-A1 | Combination Therapy For Treating Hepatitis C Infections | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| EP-2091524-A2 | COMBINATION THERAPY FOR TREATING HEPATITIS C INFECTIONS | Achillion Pharmaceuticals, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20090023730-A1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2008076443-A2 | COMBINATION THERAPY FOR TREATING HEPATITIS C INFECTIONS | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20060025416-A1 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029652-A1 | Combination Therapy For Treating Hepatitis C Infections | HAVCR2, SLC10A1, CYP7A1 | ALDH1A1 235/4885MAPK1 4242/4885SMN1; SMN2 2647/4885 |
| US-20060025416-A1 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | PIGS, NAT1, AADAC | ALDH1A1 176/4885MAPK1 3135/4885SMN1; SMN2 3029/4885 |
| US-20090023730-A1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | PIGS, NAT1, AADAC | ALDH1A1 176/4885MAPK1 3135/4885SMN1; SMN2 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.